I thought it worthwhile to revisit a rough and ready valuation i posted much earlier, which was based on a very conservative view of EBR after FDA approval, and its initial move into commercialisation.
IMO nothing has diminished in potential since that initial valuation, and in fact as more and more information has rolled out my feeling is this valuation has been based on a far too conservative approach.
But in summary that initial valuation suggested:
At a fixed US/A$ exchange rate of $0.70 - Year 1 price of $1.41,
Year 2 $2.55,
Year 3 $5.53,
based on conservative P/E multiples, initially 15, then 14, then 12.
EBR Valuations, page-15
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.035(3.06%) |
Mkt cap ! $342.0M | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.14 | $1.06 | $118.9K | 108.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| EBR (ASX) Chart |